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Recent evidence has involved cholesterol- and sphingolipid-rich membrane domains, 
termed lipid rafts, in the triggering of apoptosis by the death receptor Fas/CD95. The 
antitumor alkyl-lysophospholipid analogue edelfosine was the first drug reported to 
induce apoptosis in cancer cells through recruitment and aggregation of Fas/CD95 death 
receptor in lipid raft clusters. Co-clustering of lipid rafts and Fas/CD95 receptor was 
independent of its cognate ligand FasL/CD95L, and could be pharmacologically 
modulated. The adaptor molecule Fas-associated death domain protein (FADD) and 
procaspase-8 were also recruited at lipid rafts following edelfosine treatment, forming 
the death-inducing signaling complex (DISC), and hence these membrane 
microdomains act as scaffolds for Fas/CD95 death signaling. Edelfosine accumulated in 
lipid rafts of cancer cells, altering raft protein and lipid composition. Subsequent studies 
showed that an increasing number of antitumor drugs also were able to promote 
apoptosis through recruitment of Fas/CD95 into membrane rafts, and some of these 
compounds accumulated in raft membrane domains. Additional downstream apoptotic 
signaling molecules were also translocated into rafts following treatment of cancer cells 
with antitumor agents, thus facilitating protein-protein interactions and conveying 
apoptotic signals. On these grounds, lipid rafts have become an appealing and 
promising target for therapeutic intervention in cancer chemotherapy. Co-clustering of 
lipid rafts and Fas/CD95 signaling provides a new framework in anticancer therapy, and 
in the triggering of death receptor-mediated apoptosis, opening a new avenue in cancer 
chemotherapy. In this regard, an increasing number of patents are dealing with the 
above insights in apoptosis regulation in order to improve cancer treatment. 
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Introduction 
While investigating the mechanism of action of the antitumor phospholipid ether lipid 
edelfosine (1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, ET-18-OCH3), 
the prototype of a heterogenous family of compounds collectively known as synthetic 
alkyl-lysophospholipid analogues (ALPs) [1, 2], we found in 2000 that the induction of 
apoptosis triggered by this drug in leukemic cells was dependent on the death receptor 
Fas/CD95, which resulted aggregated in caps at the cell membrane [3]. Soon afterwards, 
we found out that edelfosine prompted translocation and co-clustering of Fas/CD95 into 
membrane rafts, thus leading to the first demonstration of the recruitment of Fas/CD95 
in lipid rafts [4], and of the involvement of membrane rafts in Fas/CD95-mediated 
apoptosis and cancer chemotherapy [4]. Membrane rafts are membrane microdomains 
of reduced fluidity consisting of dynamic assemblies of cholesterol and sphingolipids 
[5, 6]. The presence of saturated hydrocarbon chains in sphingolipids allows for 
cholesterol to be tightly intercalated, leading to the presence of distinct liquid-ordered 
phases, i.e. membrane rafts, dispersed in the liquid-disordered matrix, and thereby more 
fluid lipid bilayer. Raft disruption, following treatment with the cholesterol-depleting 
agent methyl- -cyclodextrin, inhibited both edelfosine-induced Fas/CD95 clustering 
and apoptosis [4]. This translocation and capping of Fas/CD95 into membrane rafts 
following edelfosine treatment was independent of receptor interaction with its natural 
ligand FasL/CD95L [3, 4], indicating that Fas/CD95 aggregation and activation could 
be modulated pharmacologically. Subsequent studies also showed that Fas/CD95 was 
translocated into lipid rafts following activation with FasL/CD95L [7, 8]. On these 
grounds, edelfosine mimicked to some extent the action of the natural ligand 
FasL/CD95L on promoting death receptor clustering and capping in lipid rafts. 
Activation of Fas/CD95 leads to the recruitment of the adaptor molecule Fas-associated 
 4 
death domain protein (FADD) and the zymogen procaspase-8, forming the so-called 
“death-inducing signaling complex” (DISC) [9], containing Fas/CD95, FADD and 
procaspase-8. Fas/CD95 aggregation and DISC formation leads to procaspase-8 
transactivation that releases mature caspase-8, thus initiating apoptosis through a 
subsequent caspase activation cascade [10, 11] or through cleavage of BH3-interacting 
domain death agonist (Bid) into truncated-Bid (t-Bid) [12, 13], which then triggers the 
mitochondrial signaling death pathway. The interaction of the Fas/CD95 death domain 
(DD) with the DD of the adaptor protein FADD is a critical step in assembling the 
DISC. Recent structural and biophysical approaches have revealed a core stoichiometry 
of a 5Fas/CD95:5FADD complex [14-16]. The concentration of these apoptotic 
molecules in rafts would favor formation of the above 5Fas/CD95:5FADD complex. 
The importance of lipid rafts in Fas/CD95-mediated apoptosis was further supported by 
the finding that overexpression of membrane sphingomyelin, a major component of 
lipid rafts, by transfection with sphingomyelin synthase 1 (SMS1), a gene responsible 
for sphingomyelin synthesis, enhanced Fas/CD95-mediated apoptosis through 
increasing DISC formation, activation of caspases, efficient translocation of Fas/CD95 
into lipid rafts, and subsequent Fas clustering [17]. 
On these grounds, we hypothesize that accumulation of Fas/CD95 into 
aggregates of stabilized membrane lipid domains from a highly dispersed distribution 
may represent a general mode of regulating Fas/CD95 activation. The preset review 
discuss new developments and patents that set a new framework in both apoptosis 
regulation and tumor therapy, opening a new avenue for innovation and patenting with 
implications in the clinics of cancer. 
 5 
Lipid rafts as Platforms for Fas/CD95 Signaling 
A growing amount of evidence (see sections below) points to the notion that membrane 
rafts can serve, in addition to generate a high local concentration of Fas/CD95, as 
platforms for coupling adaptor and effector proteins required for Fas/CD95 signaling. 
This is of particular significance in Fas/CD95-mediated signal transduction, as the 
initial signaling events depend on protein-protein interactions. Furthermore, this could 
facilitate and amplify signaling processes by local assembly of various cross-interacting 
signaling molecules. This mechanism of death receptor concentration in lipid rafts 
would not be only relevant to the mechanism of action of anticancer drugs, but we 
hypothesize this is a normal physiological process involved in apoptosis regulation, and 
some antitumor drugs, such as edelfosine, exacerbate this process. In this regard, 
clustering of Fas/CD95 in lipid rafts has been reported during spontaneous apoptosis of 
neutrophils [18]. 
The lipid molecule ceramide has been involved in the clustering of Fas/CD95 into 
ceramide-rich rafts [19]. However, ceramide acts as a mediator of the clustering process, 
not as an initiator of the process, amplifying the primary Fas/CD95 signaling events. Thus, 
C16-ceramide was unable to trigger Fas/CD95 clustering in the absence of stimulatory anti-
Fas/CD95 antibody or FasL/CD95L [19]. It was suggested that Fas/CD95-FasL/CD95L 
complexes entered initially into small membrane rafts and induced a weak formation of the 
DISC, leading to caspase 8 activation [19]. This rather weak caspase 8 activation would 
generate ceramide through sphingomyelinase translocation to the small lipid rafts and 
subsequent activation. Due to the high amount of sphingomyelin present in rafts (about 
70% of all cellular sphingomyelin) [20], the generated ceramide could induce coalescence 
of elementary rafts [19], leading to the formation of large patches containing Fas/CD95-
FasL/CD95L complexes that would further lead to enhanced DISC formation, thereby 
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potentiating Fas/CD95 signaling. Thus, sphingomyelinase and ceramide serve to amplify 
the signaling of Fas/CD95 at the membrane level after the initial Fas/CD95-FasL/CD95L 
interaction. 
Interestingly, it has been postulated that cholesterol-enriched rafts are transformed 
to ceramide-enriched rafts, which coalesce to larger rafts facilitating recruitment of 
Fas/CD95 death receptors and their connection with actin cytoskeleton via ezrin, followed 
by subsequent internalization and caspase activation [21, 22]. Post-translational 
modification of Fas/CD95 by palmitoylation at the membrane proximal cysteine residue 
in the cytoplasmic region (C199) is the targeting signal for Fas/CD95 localization to 
lipid rafts [23], whereas Y291 is important for Fas/CD95 internalization [24].    
 
Recruitment of Fas/CD95-Mediated Signaling in Lipid Rafts by Cancer 
Chemotherapeutic Agents  
In addition to Fas/CD95, the other two major components of DISC, namely FADD and 
procaspase-8, have been shown to be recruited into lipid rafts forming the apoptosis 
inducing complex upon incubation of tumor cells with a number of distinct antitumor 
drugs, including edelfosine [25-27], perifosine [26], cis-platin [28], resveratrol [29, 30], 
aplidin [31], rituximab [32], and avicin D [33]. Furthermore, additional downstream 
apoptotic signaling molecules, including procaspase-10, c-Jun N-terminal kinase (JNK), 
and Bid were also translocated into membrane rafts following cancer chemotherapy [25, 
26, 30, 31, 34]. As stated above, Bid has been shown to act as a bridge between 
Fas/CD95 signaling and the mitochondrial-dependent pathway of apoptosis [12, 13], 
and persistent JNK activation has been associated with apoptosis [35, 36]. The 
recruitment of JNK and Bid in membrane rafts following treatment of human leukemic 
cells with edelfosine [25] and aplidin [31] may explain the dependence of edelfosine- 
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and aplidin-mediated apoptosis on both JNK and mitochondrial signaling [36, 37]. 
Moreover, a link between the two major apoptotic signaling pathways, namely the death 
receptor-mediated extrinsic and the mitochondrial-mediated intrinsic routes following 
edelfosine treatment has been recently reported [26, 34]. 
Aggregation of death receptors in a rather small area of the cell, such as lipid raft 
membrane domains, following antitumor chemotherapy, would allow a potent synergy 
with death receptor ligands to achieve cell death. In this regard, a number of antitumor 
drugs, including resveratrol [30, 38], aplidin [31], edelfosine [26] and perifosine [26] have 
been reported to recruit death receptors Fas/CD95, tumor necrosis factor receptor 1 
(TNFR1), and TNF-related apoptosis-inducing ligand (TRAIL) receptors death receptor 
(DR) 4 and DR5 into lipid rafts, and this protein redistribution sensitized the cells to death 
receptor stimulation by their cognate ligands or agonistic cytotoxic antibodies [26, 38]. 
The above DISC apoptotic complex can also be formed with the death receptors DR4 and 
DR5 [39-41], and these TRAIL receptor-mediated DISCs are also suggested to be 
recruited into rafts following treatment with a number of antitumor drugs [26, 30, 38]. The 
above redistribution of death receptors and downstream signaling molecules into lipid 
rafts did not require protein synthesis, and therefore it was achieved from the 
preexisting protein pool [25]. 
The remarkable recruitment of death receptors, together with downstream 
apoptotic signaling molecules, in aggregated rafts has led us to coin the word CASMER 
as an acronym of “cluster of apoptotic signaling molecule-enriched rafts” [31, 34, 42, 
43]. The acronym CASMER refers to the recruitment of death receptors together with 
downstream apoptotic signaling molecules in aggregated rafts [42, 43]. The efficiency 
in promoting CASMER formation, as well as CASMER protein composition, may vary 
depending on the cell phenotype and the triggering stimulus [42, 43]. The basic protein 
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composition of CASMER includes the recruitment of death receptors in aggregated rafts 
[42, 43]. This primary CASMER requires the structure of DISC to be functionally 
active in apoptosis, thus leading to a second stage of CASMER complexity [42, 43]. 
Recent ultrastructural, genetic and pharmacologic approaches have shown the formation 
of DISC in aggregated rafts, that is forming a CASMER, and its role in apoptosis 
triggering and cancer chemotherapy [26, 27]. A third stage of complexity in CASMER 
composition involves further downstream signaling molecules, such as Bid, JNK and 
others [42-44]. Thus, CASMER represents a novel raft-based supramolecular entity, 
which seems to play a critical role in the regulation of apoptosis, acting as death-
promoting scaffolds where death receptors and downstream signaling molecules are 
brought together, thus facilitating protein-protein interactions and the transmission of 
apoptotic signals [42, 43]. On these grounds, CASMER acts as a linchpin for launching 
apoptotic signals. 
 
Lipid Rafts as a Target in Cancer Therapy 
The antitumor agents edelfosine, perifosine and aplidin, which promote a potent 
redistribution of proteins in lipid rafts leading to apoptosis [25-27, 31, 34, 45], have 
been reported to accumulate into cholesterol- and sphingolipid-rich lipid rafts [4, 25, 27, 
31, 46-48]. Edelfosine shows a high affinity for cholesterol and for cholesterol-enriched 
membranes such as rafts [49, 50], and alters the biophysical traits of raft microdomains 
in membrane model systems [50]. Thus, the antitumor drugs edelfosine, perifosine and 
aplidin, by targeting lipid rafts, reorganize these membrane domains, promoting their 
clustering and redistributing their protein content, to trigger apoptosis in a Fas/CD95-
dependent manner. This redistribution of lipid raft protein composition is cell-type 
specific. Edelfosine accumulates in lipid rafts of both human leukemic cells [25, 46] and 
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yeasts [45]. However, whereas edelfosine induces the concentration of Fas/CD95 death 
receptor and downstream signaling molecules into lipid rafts in leukemic cells [25], the 
drug selectively displaces the essential yeast plasma membrane protein Pma1p out of 
lipid rafts in Saccharomyces cerevisiae, as a major mediator of edelfosine toxicity in 
yeasts [45]. By using a Pma1p-red fluorescent protein chimera and fluorescence 
microscopy, Pma1p was found to move from the plasma membrane to intracellular 
punctuate regions, and finally localized to the yeast vacuole [45]. This Pma1p 
redistribution was preceded by the movement of sterols out of the plasma membrane 
[45]. Because the activities of proteins and signaling processes are meaningfully altered 
by changes in lipid raft biophysical properties, these findings point to a novel mode of 
action for an anti-cancer drug, through modification of plasma membrane lipid 
composition resulting in the displacement of an essential protein from lipid rafts in 
yeasts [45]. Current evidence shows that selective reorganization of lipid rafts, leading 
to recruitment or displacement of critical proteins, regulates the cell fate, indicating that 
lipid rafts act as controllers of cell death by subcellular redistribution of proteins and 
lipids [25, 45, 51]. 
In addition, one of the characteristic features of tumor membranes is altered 
concentration of gangliosides and their overexpression in tumor progression [52-55]. 
Interestingly, a strong affinity of edelfosine to ganglioside GM1, a major component of 
lipid rafts, has been recently reported [56]. On these grounds, it could be envisaged that 
overexpression of gangliosides in tumor cells might facilitate the preferential affinity of 
edelfosine for cancer cell rafts overexpressing gangliosides [57]. Taken altogether, the 




In Vivo Involvement of Cholesterol-Rich Rafts in Cancer Chemotherapy 
Very recently, we have shown evidence in tumor xenograft animal models for a potent 
antitumor activity of edelfosine oral administration, and the drug accumulated 
preferentially and dramatically in the tumor [48, 58]. Following edelfosine oral 
administration in non-tumor-bearing mice, a rather wide drug distribution pattern to 
several tissues, including lung, spleen, intestine, liver and kidney, was observed [59]. 
However, when severe combined immune deficiency (SCID) mice were injected with 
human mantle cell lymphoma, chronic lymphocytic leukemia, or multiple myeloma 
xenografts, edelfosine distribution was dramatically shifted towards the tumor, 
indicating a rather selective tumor targeting for edelfosine [48, 58]. No apparent damage 
in the distinct organs analyzed following necropsy in the above in vivo studies was 
detected [48, 58]. Furthermore, edelfosine lacked toxicity in rats by using histologic, 
functional and biochemical parameters [60]. A decrease in tumor cell cholesterol, a 
major raft component, inhibited the in vivo antimyeloma action of edelfosine and 
reduced drug uptake by the tumor [48]. These data provided the proof-of-principle and 
rationale for further clinical evaluation of edelfosine and for this cholesterol-rich raft-
targeted therapy to improve patient outcome in cancer [48]. These data also revealed 
cholesterol-rich lipid rafts as a novel and efficient therapeutic target in multiple 
myeloma, opening a new avenue in cancer treatment [48]. Furthermore, the small 
tumors isolated from edelfosine-treated mice were poorly vascularized. This might be in 
agreement with reports showing an antiangiogenic effect of edelfosine [61]. 
The finding that edelfosine binds to cholesterol-rich rafts is of particular 
importance as the cholesterol content in tumor cells has been shown to be higher than in 
normal cells [62-65]. Furthermore, cancer cells have been reported to display higher 
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levels of cholesterol-rich lipid rafts than their normal counterparts [66]. The ability of 
edelfosine to interact with cholesterol may have interesting biomedical applications, as 
lipid rafts are involved in a number of distinct biological processes with important 
biomedical consequences [67]. Taken together, the above evidences on the high 
cholesterol content of tumor cells and the avidity for cholesterol of edelfosine might 
explain, at least in part, the efficient and selective action of edelfosine as an antitumor 
agent [3, 68, 69], the critical role of cholesterol-rich rafts in edelfosine anticancer 
action, the preferential accumulation of edelfosine in tumor cells as well as the apparent 
lack of toxicity exerted by this phospholipid ether in animal models. 
 
Lipid Rafts in Cancer 
Lipid rafts are small (10-200nm) heterogenous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalize cellular processes. One of the 
most important role of lipid rafts at the cell surface is their function in signal 
transduction. Rafts act as scaffolds or concentrating platforms, and thus they facilitate 
protein interaction and signal transmission. In addition, if the constituents of a specific 
signaling route were brought together in a lipid raft, the resulting signaling complex 
and/or protein-protein interactions might be protected from non-raft proteins, that 
otherwise could negatively affect the signaling process. This is particularly important 
when phosphorylation processes are critical in conveying signals, taking apart both 
kinases and phosphatases. In this regard, a number of receptor- and tyrosine 
phosphorylated-mediated signaling processes (e.g.: IgE signaling, T-cell receptor, 
epidermal growth factor receptor, insulin receptor), which are critical for cell survival 
and immune response, occur in lipid rafts [5].  
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The phosphoinositide 3-kinase (PI3K)/Akt pathway is essential for cellular 
physiology and cell survival [70]. The serine/threonine kinase Akt (a.k.a. protein kinase 
B, PKB), is a central component of survival signaling, which has a multiple-step 
activation process [71-73]. Upon receptor-mediated activation, PI3K generates 
phosphatidylinositol-3,4,5-triphosphate (PIP3) through phosphorylation of 
phosphatidylinositol-4,5-bisphosphate (PIP2). The pleckstrin homology (PH) domain of 
Akt specifically recognizes PIP3, triggering Akt recruitment from the cytosol to the 
plasma membrane. Once in contact with the membrane, Akt undergoes an activation 
process involving phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) and 
PDK2 [72, 73]. Akt is then released from the membrane and phosphorylates both 
cytosolic and nuclear targets. The interaction of Akt with PIP3 is therefore required for 
activation of Akt, by triggering its translocation to the plasma membrane. Both Akt [74, 
75] and the PDKs [76, 77] have been reported to partition into rafts. Thus, lipid rafts 
play a crucial role in triggering the PI3K/Akt signaling pathway, by facilitating Akt 
recruitment and activation upon PIP3 accumulation in the plasma membrane. In this 
regard, through direct monitoring and controlled alterations of rafts in living cells, lipid 
rafts have been demonstrated to be critically involved in the membrane recruitment and 
activation of Akt/PKB signaling, which plays a major role in cell physiology [78, 79]. 
Increasing evidence suggests that integrity of lipid rafts is essential for Akt/PKB 
activation and regulation of cell death [79, 80]. 
Lipid rafts seem to play a crucial role in tumor development. Data from prostate 
tumor animal models have shown that raising or lowering cholesterol, a critical 
component of rafts [81, 82], led to tumor growth promotion or inhibition, respectively 
[83, 84]. Lipid raft cholesterol regulates apoptotic cell death in prostate cancer cells, 
through epidermal growth factor receptor (EGFR)-mediated Akt and extracellular 
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signal-regulated kinase (ERK) pathways [85]. Increased levels of cholesterol-rich lipid 
rafts in cancer cells have also been reported to correlate with apoptosis sensitivity 
induced by cholesterol-depleting agents [66]. 
Edelfosine and perifosine are members of a family of compounds collectively 
known as antitumor alkyl-lysophospholipid analogues (ALPs). Distinct ALPs have been 
reported to potently inhibit Akt activation [86, 87], and also involve Fas/CD95 signaling 
[3, 4, 25, 26, 88]. On these grounds, ALPs are able to target lipid rafts leading to both 
death receptor signaling activation and Akt survival signaling inhibition. Thus, it might 
be envisaged that, by targeting lipid rafts, ALPs may activate pro-death and inhibit pro-
survival pathways simultaneously Fig. (1). 
 
Modulation of Survival and Apoptotic Signaling in Rafts by Edelfosine 
Novel data suggest that apoptosis/survival signaling balance might be modified by a 
redistribution and local accumulation of apoptotic molecules in lipid rafts, setting apart 
apoptotic (Fas/CD95, FADD, caspase-8, JNK) from survival (ERK, Akt) signaling 
molecules [89]. In this regard, edelfosine treatment in T-cell leukemia Jurkat cells led to 
a recruitment of heat shock protein 90 (Hsp90) and JNK in lipid rafts, thus preserving 
sustained JNK activation, and identifying JNK as a novel Hsp90 client protein when 
both molecules were concentrated in rafts [89]. Hsp90 is a molecular chaperone, 
overexpressed in many tumor cells, that keeps the correct folding and function of 
various client proteins that promote cancer cell growth, including HER-2/Erb2, Akt, 
Raf-1, Bcr-Abl, and mutated p53 [90]. However, edelfosine treatment apparently took 
apart Hsp90 from their normal client survival proteins, and recruited this chaperone to 
rafts where apoptotic molecules were concentrated [89], forming a CASMER [42, 43], 
hence turning this chaperone into a stabilizer of apoptotic signaling. This concentration 
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of apoptotic molecules, separated from survival signaling molecules, leads to a dramatic 
local change in the apoptosis/survival signaling ratio in a specific subcellular structure 
that eventually triggers a cell death response Fig. (1). In this regard, segregation in 
membrane rafts of pro- from anti-apoptotic insuline-like growth factor-I receptor 
signaling in colon carcinoma cells by members of the tumor necrosis factor superfamily 
has been reported [91]. Likewise, edelfosine leads to cell death in S. cerevisiae by 
displacement of Pma1p, a critical yeast survival protein, from lipid rafts [45]. Thus, 
lipid rafts serve as a potential pharmacological target in the treatment of cancer. 
 
Patents Involving the Participation of Rafts in the Regulation of Cell Death 
A number of recent patents involve the modulation of lipid rafts by distinct 
pharmacological agents. In particular, some novel patents are directed to the modulation 
of lipid raft-mediated functions and processes by platinum and sphingolipid-derived 
compounds [92, 93]. Lipid rafts are associated with membrane and cellular transport, 
cell membrane receptor function, cellular trafficking, antigen presentation, cell 
differentiation and activation, cytokine modulation, membrane structure and function, 
and protein modulation, and therefore these membrane domains are therapeutic targets 
for numerous biological functions. Diseases and disorders currently known to be 
therapeutically targeted through lipid rafts include diabetes, cancer, cardiovascular 
diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion 
diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune 
disorders [92]. On these grounds, some patents have been reported to regulate cell death 
through modulation of lipid rafts in both cancer [94], by interfering with insulin growth 
factor-I receptor signaling, and neurodegenerative diseases [95, 96]. 
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Because the displacement of certain raft proteins from lipid rafts can lead to 
apoptosis [45, 51, 97], a patent has reported a screening method to identify new 
apoptosis modulating compounds [98]. In addition, because lipid rafts are dynamic 
structures that are internalized during cell function, a patent describes the use of 
synthetic lipid rafts to deliver polynucleotides, proteins, therapeutic agents, or a 
combination thereof to specific membrane-bound compartments of a cell [99]. In certain 
aspects, the synthetic vesicles were reported to deliver cargo to cellular organelles such 
as mitochondria [99]. 
 
New Patents Involving ALPs and Their Putative Action on Lipid Rafts      
Edelfosine was the first compound reported to promote apoptosis by ligand-independent 
activation of Fas/CD95 death receptors, via their recruitment in lipid rafts, and to target 
lipid rafts in tumor cells [3, 4, 25-27, 46, 48, 58]. Because studies conducted to uncover 
the edelfosine mechanism of action have contributed most to defining the processes 
taking place to promote apoptosis mediated by rafts, this ether phospholipid can be 
considered as a paradigm in raft-mediated cancer chemotherapy that leads to cell death. 
Edelfosine has been shown to be incorporated in a rather selective way by tumor cells 
[3, 26, 68, 69]. How edelfosine is taken up by tumor cells remains to be elucidated, but 
evidence so far indicates that drug incorporation proceeds through a raft- and protein-
mediated process [25-27, 46, 69]. This selectivity, together with the apparent lack of 
significant toxicity in animal model studies [48, 58, 60], suggest that edelfosine is a 
good drug candidate for prolonged treatments. A problem in cancer treatment consists 
in the limited duration of the use of a therapy. The toxicity of the currently available 
drugs, or therapeutic approaches, permits their use only in cycles, and for a limited time. 
Edelfosine, due to its unique traits, could be allegedly used over a very prolonged 
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period of time, because of its selectivity and lack of toxicity. Edelfosine has been shown 
to exhibit anti-invasive activity in glioblastoma cells [100]. Interestingly, increasing 
evidence suggests a role for lipid rafts in metastasis [101-106]. In this regard, ALPs 
have been shown to inhibit metastasis and cell invasion [107-113], and a patent showed 
that edelfosine treatment could be useful and feasible for long-term palliative treatment 
of brain tumors, leading to a tumor stabilization in a high proportion of patients that had 
received several previous treatments [114]. During this phase II study [114], the adverse 
drug reactions caused by edelfosine therapy were rather mild and had a short duration. 
Adverse drug reactions often appeared in the first two months of the therapy, and then 
disappeared entirely. However, in every case, the observed symptoms were reversible 
within a very short period of time [114]. No cumulative toxicity, even after several 
years of uninterrupted therapy, was reported [114]. Previous clinical trials with 
edelfosine showed that hematological or systemic side-effects, such as 
myelosuppression, nephro-, neuro- or hepatotoxicity, were rarely observed, even after 
prolonged therapy [1, 67, 115]. 
 We have found that multiple oral administration is required to increase oral 
bioavailability of edelfosine [116]. In human serum, edelfosine bound to several protein 
components, primarily high density lipoprotein and albumin, and this may explain why 
cellular uptake is slowed considerably by the presence of serum or albumin in the 
incubation medium [117]. 
Hemolysis was a major side effect of edelfosine when applied intravenously 
[118]. This hemolytitc activity could be prevented by patented and stable liposome-
based formulations of edelfosine [67, 119]. In mixtures with certain lipids, particularly 
sterols, edelfosine retained its apoptotic properties, while reduced its hemolytic side 
effect [49]. It has also been shown that, in those binary mixtures that abolish hemolysis, 
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edelfosine is slowly released from the lipid mixture to the aqueous environment [49]. 
The fact that the slow release of edelfosine reduces or abolishes haemolysis, while 
keeping almost intact its apoptotic effect, suggests that both phenomena occur through 
different mechanisms. The molecular geometry of the lipid molecules dictates the 
structure of the lipid aggregates [120]. In this regard, the bilayers arising from the 
combination of conical and inverted conical molecules (e.g. sterols + edelfosine) appear 
to be more stable than those containing cylindrical and inverted conical lipids (e.g. 
phosphatidylcholine + edelfosine); thus, edelfosine release is slower in the former case 
[49]. 
Edelfosine shows a high affinity for cholesterol and for cholesterol-enriched 
membranes such as rafts [49, 50], due, as stated above, to the complementarity of the 
molecular geometrics of sterols and edelfosine [49]. The high cholesterol content in 
tumor cells, together with the avidity for cholesterol of edelfosine, might contribute in 
part to the accumulation of edelfosine in tumor cells. Nevertheless, the uptake of 
edelfosine by tumor cells has been suggested to be mediated by a putative protein 
transporter [69], which has been identified as Lem3p in Saccharomyces cerevisiae yeast 
[121]. It might be envisaged that tumor cells could undergo a series of changes in lipids, 
including cholesterol, and proteins, including transporters, that could affect raft 
organization in a way that facilitates edelfosine uptake. A recent patent [122] took 
advantage of the selective uptake of ALPs by tumor cells, and used phospholipid ether 
analogues labeled with a halogen radioisotope as radiolabeled tumor-specific agents to 
functionally identify malignant tissues and as a therapeutic option. Additional targeting 
vector-phospholipid conjugates are being synthesized for both therapeutic and 
diagnostic goals [123]. 
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The fact that edelfosine and other ALPs target and act through lipid rafts [4, 25, 
27, 46, 47, 50], together with the involvement of these membrane domains in a wide 
number of critical cellular functions, has allowed to issue a growing number of patents 
for ALPs for distinct biomedical applications [67]. In this regard, a recent patent has 
taken advantage of the role of lipid rafts in IgE receptor signaling to report a method to 
affect allergic diseases, including asthma, through pharmacological modulation of rafts, 
including the ALPs miltefosine and edelfosine [124]. Another patent claims for the anti-
inflammatory action of edelfosine, mainly due to shedding of the raft-located L-selectin 
protein [60, 125]. 
 Because membrane raft microdomains play a key role in the activation of death 
receptors and the triggering of apoptosis, the recruitment of death receptors together 
with downstream apoptotic signaling molecules in rafts, leading to CASMER formation 
[42, 43], sets a new insight in cancer therapy. Because this CASMER formation triggers 
the apoptotic machinery, the potential for raft- or CASMER-based therapies seems very 
promising in the treatment of cancer. In addition, this raft-mediated process might 
facilitate and potentiate combination therapy [26]. In this regard, a number of patents 
describe the use of combination therapy with perifosine, which has been reported to act 
through lipid rafts [26], to improve cancer treatment [126, 127].  
 
Current & Future Developments 
Recent in vitro and in vivo data have identified lipid rafts as a novel and effective 
therapeutic target in some tumors, setting a novel framework in cancer chemotherapy 
[4, 25-27, 44, 48, 58]. The antitumor ether phospholipid edelfosine was the first raft-
targeted drug, accumulating in lipid rafts and triggering the demise of cancer cells. 
Hence edelfosine can be considered as the paradigm for this new raft-targeted 
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anticancer therapeutic approach. The accumulation of edelfosine in rafts might be 
explained, in part, by its high affinity for cholesterol [49, 50], due to geometry 
compensation of the “cone shape” of sterols and the “inverted cone shape” of edelfosine 
that leads to a stable bilayer [49]. Edelfosine targets membrane rafts of malignant cells, 
inducing raft aggregates that act as scaffolds for the recruitment and concentration of 
Fas/CD95 and TRAIL receptors. Previous reports have shown that a number of tumor 
cells, including multiple myeloma cells, express Fas/CD95, but are rather resistant to 
undergo apoptosis in response to the external stimulation of Fas/CD95 by agonistic anti-
Fas/CD95 antibodies [128]. However, edelfosine activates Fas/CD95 and induces its 
aggregation in rafts from within the cell independently of its ligand [25], triggering 
subsequently downstream extrinsic and intrinsic signaling pathways that eventually lead 
to apoptosis [3, 4, 25-27, 34, 129]. Subsequent studies have allowed to extend the raft-
mediated antitumor therapy, initially described with edelfosine, to an increasing number 
of therapeutic drugs [42-44]. Elucidation of the molecular mechanism involved in the 
action of raft-targeted drugs, and synthesis of new compounds that efficiently achieve a 
raft-mediated apoptotic response in tumor cells, are promising and novel approaches in 
cancer therapy. This raft-mediated cancer therapy is different from the previous and 
currently chemotherapy programs based on targeting DNA or cell cycle-related 
processes, and could circumvent drug resistance as it prompts a rather direct apoptotic 
response in the cancer cell.  
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LIST OF ABBREVIATIONS 
ALPs  =  Alkyl-lysophospholipid analogues 
Bid  =  BH3-interacting domain death agonist 
CASMER  =  Cluster of apoptotic signaling molecule-enriched rafts 
DD  =  Death domain 
DISC  =  Death-inducing signaling complex 
DR  =  Death receptor 
EGFR  =  Epidermal growth factor receptor 
ERK  =  Extracellular signal-regulated kinase 
ET-18-OCH3  =  1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine, edelfosine 
FADD   =  Fas-associated death domain protein 
FasL  =  Fas ligand 
JNK  =  c-Jun N-terminal kinase 
PDK1  =  Phosphoinositide-dependent kinase 1 
PH  =  Pleckstrin homology 
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PI3K  =  Phosphoinositide 3-kinase 
PIP2  =  Phosphatidylinositol-4,5-bisphosphate 
PIP3  =  Phosphatidylinositol-3,4,5-triphosphate 
PKB  =  Protein kinase B  
SCID  =  Severe combined immune deficiency 
SMS1  =  Sphingomyelin synthase 1 
t-Bid  =  Truncated Bid 
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Figure 1. ALP-mediated anticancer activity via rafts. This scheme depicts a plausible 
model for the action of Alps trough lipid rafts. ALPs interact with lipid rafts, and 
promote their clustering and reorganization of their protein composition. This 
leads to the activation of apoptotic signaling, including CASMER formation, 
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